Phase IV Commitments Should Be Enforced By Civil Penalties, Not Withdrawal

FDA expects to propose civil monetary penalties as one enforcement option for companies failing to fulfill postmarketing commitments, in lieu of removing the drug from the market.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet